If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 10 of 15

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Ma

Screening Protocol for Tumor Antigen Expression Profiling and HLA typing for Eligibility
Protocol No
ADP-0000-001-SCR
Categories
Cancer, Gynecologic Cancers, Prostate and Urologic Cancers, Other Respiratory, Lung, Esophagus, Other Skin, Melanoma, Skin, Other Urologic, Bladder, Lip, Oral Cavity and Pharynx, Larynx, Other Gynecologic, Ovary, Thoracic Cancers, Sarcoma, Skin Cancers, Head and Neck Cancers, Gastrointestinal Cancers, Cervix, Other Gastrointestinal, Stomach, Pancreas/Liver, Esophagus, Colorectal

High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)

A Phase II study of Re-Irradiation Utilizing DIR and OAR Dose Calculations with Organ Specific Toxicity Analysis
Protocol No
IIT-GORE-REDIRICT
Categories
Cancer, Colorectal, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Endocrine Cancers, Breast Cancers, Brain and Spine Cancers, Other Respiratory, Lung, Esophagus, Other Skin, Melanoma, Skin, Other Urologic, Bladder, Prostate, Kidney, Lip, Oral Cavity and Pharynx, Larynx, Other Gynecologic, Uterine, Ovary, Cervix, Other Gastrointestinal, Stomach, Pancreas/Liver, Esophagus

A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 as Monotherapy in Patients with Locally Advanced or Metastatic Solid Tumors

A Phase 1 Study of Spyk04 as Monotherapy in Patients with Solid Tumors
Protocol No
CHUGAI-SPK101JG
Categories
Cancer, Ovary, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gastrointestinal Cancers, Breast Cancers, Lung, Esophagus, Other Skin, Melanoma, Skin, Other Urologic, Bladder, Prostate, Kidney, Lip, Oral Cavity and Pharynx, Larynx, Other Gynecologic, Uterine, Cervix, Other Gastrointestinal, Stomach, Pancreas/Liver, Esophagus, Colorectal, Gynecologic Cancers

A Phase 1, Open Label First in Human Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK 1 Inhibitor GRC 54276 Alone and in Combination with Anti-Pd-1 Monoclonal Antibody Pembrolizumab or Anti-Pd-

A Phase 1 Study of Hpk1 GRC54276 in Combination with Anti-Pd-1 in Patients with Advanced Solid Tumors
Protocol No
GLENMARK-GRC-54276-101
Categories
Cancer, Lung, Esophagus, Other Skin, Melanoma, Skin, Other Urologic, Bladder, Prostate, Kidney, Lip, Oral Cavity and Pharynx, Larynx, Other Gynecologic, Uterine, Ovary, Cervix, Other Gastrointestinal, Stomach, Pancreas/Liver, Esophagus, Colorectal, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Endocrine Cancers, Breast Cancers

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRAS G12C Mutant Advanced Solid Tumors

This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
Protocol No
MERCK-MK1084-001
Categories
Cancer, Colorectal, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Eye/Orbital Cancers, Endocrine Cancers, Breast Cancers, Lung, Esophagus, Other Skin, Melanoma, Skin, Other Urologic, Bladder, Prostate, Kidney, Lip, Oral Cavity and Pharynx, Larynx, Other Gynecologic, Uterine, Ovary, Cervix, Other Gastrointestinal, Stomach, Pancreas/Liver, Esophagus

A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers

This study is to investigate the study drug in patients with a specific type of cancer called human papillomavirus 16-positive (HPV 16+) cancers. HPV 16+ cancers include head and neck, cervical, anal, vaginal, vulvar, and penile cancers. The main goal of the study is to determine whether HB-201 and HB-202 are effective in the treatment of human papillomavirus 16 positive (HPV 16+) confirmed cancers.
Protocol No
HOOKIPA-H-200-001
Categories
Cancer, Cervix, Early Phase/Multiple Disease Site Cancers, Head and Neck Cancers, Gynecologic Cancers, Lip, Oral Cavity and Pharynx, Larynx, Other Gynecologic

A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination with Nivolumab or Standard of Care in Patients with Locally Advanced or Metastatic Solid Tumors

This project is being done to find out the highest tolerable dose of TST001 that can be given to patients when given via IV once every 2 or 3 weeks, what are the side effects, how much TST001 is in the blood at a specific times after dosing and how does the body get rid of it.
Protocol No
MABSPACE-TST001-1001
Categories
Cancer, Cervix, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Eye/Orbital Cancers, Endocrine Cancers, Breast Cancers, Lung, Esophagus, Other Skin, Melanoma, Skin, Other Urologic, Bladder, Prostate, Kidney, Lip, Oral Cavity and Pharynx, Larynx, Other Gynecologic, Uterine, Ovary

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors

To assess the safety, tolerability, dose-limiting toxicities (DLTs), and determine the maximum tolerated dose of INBRX-106 as a single agent administered as an intravenous infusion and in combination with pembrolizumab.
Protocol No
INHIBRX-PH1-INBRX-106
Categories
Cancer, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Melanoma, Skin, Kidney, Other Gynecologic, Other Gastrointestinal